Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.

[1]  Rebecca J. Cope,et al.  Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity , 2023, American journal of therapeutics.

[2]  S. Samajdar,et al.  Effects of Saroglitazar in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review and Meta-analysis. , 2023, Clinics and research in hepatology and gastroenterology.

[3]  L. Ren,et al.  Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis , 2023, Frontiers in Endocrinology.

[4]  A. Sanyal,et al.  Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial , 2023, The lancet. Gastroenterology & hepatology.

[5]  J. Ena,et al.  Efecto de semaglutida sobre los biomarcadores de la enfermedad del hígado graso en pacientes con diabetes y obesidad , 2023, Revista Clínica Española.

[6]  L. Henry,et al.  The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review , 2023, Hepatology.

[7]  R. Marfella,et al.  GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives , 2023, International journal of molecular sciences.

[8]  G. De Pergola,et al.  Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study , 2022, Nutrients.

[9]  T. Wadden,et al.  Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial , 2022, Nature Medicine.

[10]  S. Sullivan,et al.  Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States , 2022, Journal of managed care & specialty pharmacy.

[11]  A. Tsubota,et al.  Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study , 2022, JGH open : an open access journal of gastroenterology and hepatology.

[12]  H. Tilg,et al.  Current therapies and new developments in NASH , 2022, Gut.

[13]  T. Hassanein,et al.  Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. , 2022, Journal of hepatology.

[14]  Y. Hiasa,et al.  Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study , 2022, Diabetes Therapy.

[15]  P. Hockings,et al.  Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging , 2021, Alimentary pharmacology & therapeutics.

[16]  K. Cusi,et al.  The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD , 2021, The Journal of clinical endocrinology and metabolism.

[17]  G. Targher,et al.  Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. , 2021, Hepatobiliary surgery and nutrition.

[18]  D. V. van Raalte,et al.  Safety of Semaglutide , 2021, Frontiers in Endocrinology.

[19]  B. Sinha,et al.  A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) , 2021, Scientific Reports.

[20]  He He,et al.  Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis , 2021, Frontiers in Endocrinology.

[21]  A. Lonardo,et al.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials , 2021, Metabolites.

[22]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[23]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[24]  T. Cotter,et al.  NAFLD 2020: The State of the Disease. , 2020, Gastroenterology.

[25]  B. Wolffenbuttel,et al.  Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands , 2019, BMJ Open Diabetes Research & Care.

[26]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[27]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[28]  L. V. Van Gaal,et al.  Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity , 2019, Alimentary pharmacology & therapeutics.

[29]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[30]  T. Vilsbøll,et al.  Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD , 2018, Front. Endocrinol..

[31]  F. Folli,et al.  Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). , 2018, Pharmacological research.

[32]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[33]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[34]  G. Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[35]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[36]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[37]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[38]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[39]  C. Mantzoros,et al.  Non-alcoholic fatty liver disease and dyslipidemia: An update. , 2016, Metabolism: clinical and experimental.

[40]  S. Gough,et al.  Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis , 2016, Journal of hepatology.

[41]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[42]  C. Beglinger,et al.  Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease , 2014, PloS one.

[43]  Xin-chun Yang,et al.  Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. , 2013, Arquivos brasileiros de endocrinologia e metabologia.

[44]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[45]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[46]  K. Cusi.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[47]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[48]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[49]  Z. Goodman,et al.  Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  W. Goessling,et al.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. , 2008, Gastroenterology.

[51]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[52]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[53]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.